In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…... [Read More]
Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
Search results for: psoriasis
Tildrakizumab Promising for Psoriasis in Patients with PsA
New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…... [Read More]
Rheumatology Drugs at a Glance, Part 2: Psoriasis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to… [Read More]
IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…... [Read More]
Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…... [Read More]
Mirikizumab Promising for Plaque Psoriasis
During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…... [Read More]
For Psoriasis, Ustekinumab & TNF Inhibitors Show Similar Cardiac Safety
NEW YORK (Reuters Health)—In patients with psoriasis and psoriatic arthritis, the incidence of atrial fibrillation and major adverse cardiovascular events does not differ between treatment with ustekinumab and TNF inhibitors, according to a large observational study. “Given a high cardiovascular risk among patients with psoriasis and psoriatic arthritis,” Seoyoung C. Kim, MD, ScD, MSCE, told… [Read More]
FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review
The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…... [Read More]
Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence
According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…... [Read More]
Piclidenoson in Trials for Psoriasis & RA; Plus Duzallo Approved in Europe
New clinical trials are underway to determine the safety and efficacy of piclidenoson for patients with plaque psoriasis and rheumatoid arthritis…... [Read More]
- 1
- 2
- 3
- …
- 41
- Next Page »